echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Temozolomide for injection, a subsidiary of Xintian Pharmaceutical's shareholding company, obtained drug registration approval

    Temozolomide for injection, a subsidiary of Xintian Pharmaceutical's shareholding company, obtained drug registration approval

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 22, Xintian Pharmaceutical issued an announcement stating that Huilun Jiangsu Pharmaceutical, a wholly-owned subsidiary of its shareholding company Huilun Biotechnology, had recently received the "Drug Registration Certificate" for temozolomide for injection approved and issued by the State Drug Administration ( Batch number: 2021S00983)


    Temozolomide is a new type of alkylating agent anti-tumor drug, which is mainly used for the treatment of glioma.


    Compared with temozolomide in oral capsules, temozolomide for injection can provide medication for patients who need chemotherapy but inconvenient oral medication and have difficulty swallowing, and reduce the insufficiency of drug absorption due to vomiting of temozolomide in oral capsules, which affects the therapeutic effect


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.